All In Biotech

Drug Trial Radar · NCT02687906

Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections

An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

39

Actual

Start

Jul 2016

Primary completion

Jul 2026

Study completion Jul 15, 2026

Sponsor

Sponsor type
Industry
Collaborators
Department of Health and Human Services
First posted
Feb 22, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections

Conditions

  • Bacterial Infections

Interventions

  • VabomereDrug

    Vabomere (meropenem-vaborbactam) for IV injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics: AUC0-∞Time frame: From pre-dose until 6 hours after the start of the infusion
  2. Pharmacokinetics: CmaxTime frame: From pre-dose until 6 hours after the start of the infusion
  3. Pharmacokinetics: time to maximum plasma concentration (Tmax)Time frame: From pre-dose until 6 hours after the start of the infusion
  4. Pharmacokinetics: drug clearance (CL)Time frame: From pre-dose until 6 hours after the start of the infusion
  5. Pharmacokinetics: t1/2Time frame: From pre-dose until 6 hours after the start of the infusion
  6. Pharmacokinetics: CminTime frame: From pre-dose until 6 hours after the start of the infusion
  7. Pharmacokinetics: VssTime frame: From pre-dose until 6 hours after the start of the infusion
  8. Safety and tolerability: AEs/SAEsTime frame: From assent / consent until day 7 safety follow up call
  9. Safety and tolerability: clinical safety laboratory resultsTime frame: From assent / consent until day 7 safety follow up call
  10. Safety and tolerability: vital signsTime frame: From assent / consent until day 7 safety follow up call
  11. Safety and tolerability: ECGsTime frame: From assent / consent until day 7 safety follow up call

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • Children's Hospital of Orange County

    Orange, California

  • Rady Children's Hospital San Diego

    San Deigo, California

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Rutger's University

    New Brunswick, New Jersey

  • Rainbow Babies and Childrens Hospital

    Cleveland, Ohio

  • Toledo Children's Hospital

    Toledo, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.